Christophe Massard
- Oncology top 2%
- Surgery top 5%
- Pulmonary and Respiratory Medicine top 10%
- Immunology top 10%
- Molecular Biology
- Co-authors
- Peter H. O’DonnellXiaoping JinAshok GuptaJingsong ZhangTerence W. FriedlanderJae‐Lyun LeeJoyce AntalNoah M. Hahn
- Topics
- Testicular diseases and treatments (14 papers)Bladder and Urothelial Cancer Treatments (8 papers)Cancer Immunotherapy and Biomarkers (7 papers)
- Cited by
- OncologySurgeryImmunology
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Christophe Massard
25 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 63
- Oncology 1.2k
- Surgery 1.1k
- Pulmonary and Respiratory Medicine 360
- Immunology 340
- Molecular Biology 194
Countries citing papers authored by Christophe Massard
This map shows the geographic impact of Christophe Massard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Massard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Massard more than expected).
Fields of papers citing papers by Christophe Massard
This network shows the impact of papers produced by Christophe Massard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Massard. The network helps show where Christophe Massard may publish in the future.
Co-authorship network of co-authors of Christophe Massard
This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Massard. A scholar is included among the top collaborators of Christophe Massard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Massard. Christophe Massard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 3 | |
| 4 | 18 | |
| 5 | 2 | |
| 6 | 7 | |
| 7 | 1 | |
| 8 | 0 | |
| 9 | 6 | |
| 10 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancerbreakdown → | 661 |
| 11 | 0 | |
| 12 | 1 | |
| 13 | 23 | |
| 14 | 0 | |
| 15 | 19 | |
| 16 | 7 | |
| 17 | 21 | |
| 18 | 29 | |
| 19 | 14 | |
| 20 | 1 |
About Christophe Massard
Christophe Massard is a scholar working on Surgery, Oncology and Rheumatology, having authored 30 papers that have together received 1.8k indexed citations. Recurring topics across this work include Testicular diseases and treatments (14 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Oncology (1.2k citations), Surgery (1.1k citations) and Immunology (340 citations). Christophe Massard has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Peter H. O’Donnell, Xiaoping Jin, Ashok Gupta, Jingsong Zhang, Terence W. Friedlander, Jae‐Lyun Lee, Joyce Antal, Noah M. Hahn, Mayer Fishman and Michael Ong. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.